Daniel Hunt

Daniel Hunt has held various leadership roles in the biotechnology and finance sectors, currently serving as the VP of Corporate & Business Development at Allogene Therapeutics since August 2018. Additionally, Daniel holds board positions at Overland Therapeutics and Antion Biosciences SA, and has experience as a board observer and member at Notch Therapeutics. Previous experience includes VP of Corporate Development at Fluidigm Corporation and positions at Biotechnology Strategic & Market Research, Allianz Global Investors, Cowen and Company, and Thomson Reuters. Daniel earned a Bachelor’s degree from Stanford University and a Master’s degree from The London School of Economics and Political Science.